FTC Warns Drugmakers Against Listing Illegitimate Patents
The Federal Trade Commission voted unanimously Thursday to issue a policy statement cautioning drug manufacturers against listing noncompliant drug patents in the U.S. Food and Drug Administration's Orange Book, part of...To view the full article, register now.
Already a subscriber? Click here to view full article